U.S. companies that are working on coronavirus treatments or vaccines
A mix of legacy drug makers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first detected in December in Wuhan, China, has sickened more than 1,150,000 people worldwide and killed at least 64,500. There are no approved vaccines or therapies for the disease although the use of hydroxychloroquine sulfate and chloroquine phosphate to treat COVID-19 patients is authorised.
Many of the U.S. companies that are initiating development have received funding from two organizations: the Biomedical Advanced Research and Development Authority (BARDA), which is a division of the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health. Some companies have also received funding from Coalition for Epidemic Preparedness Innovations (CEPI), a global organization based in Oslo that has provided millions of dollars in funding to vaccine makers. Other companies are funding trials by themselves or through partnerships with other life sciences companies.